How to Use The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas and Online Gallery
Are you in need of inclusive and diverse images representing various skin tones for your lectures or presentations? We have you covered. Check out this “How To” tutorial for The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas Online Gallery. This comprehensive resource features over 100 common skin conditions, showcasing royalty-free images that require no permission for non-commer …
Are you in need of inclusive and diverse images representing various skin tones for your lectures or presentations? We have you covered. Check out this “How To” tutorial for The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas Online Gallery. This comprehensive resource features over 100 common skin conditions, showcasing royalty-free images that require no permission for non-commer … 
October's Journal of Drugs in Dermatology Editor's Picks offer an exciting look into cutting-edge research, with a special focus on atopic dermatitis and several related skin conditions. This month’s selections dive deep into groundbreaking studies, ranging from innovative treatments for acne and environmental skin aging to advancements in hyperhidrosis research using machine learnin … 
The September edition of the Journal of Drugs in Dermatology (JDD) focuses on aesthetic treatments, exploring the latest advancements and innovative approaches that are reshaping dermatologic care. This month’s Editor's Picks bring together a selection of cutting-edge research, from the use of genomic analysis in melanoma management to AI’s influence on beauty standards.
Explore the latest … 
A study in the August Journal of Drugs in Dermatology addressed the burden of melasma – the populations most prone to melasma and the comorbidities associated with it. According to the study’s authors, a deeper understanding of the associations of race, ethnicity and comorbidities can help dermatologists determine which patients are at risk of developing melasma and as well as potential new pa … 
Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was FDA-approved in 2017 for treatment of type II diabetes and in 2021 for treatment for chronic weight management in adults with obesity or overweight with at least one weight-related condition.1 Due to its longer duration of action, it is typically administered subcutaneously once weekly. The safety profile of semaglutide is similar to … 